Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): Results from a multicenter phase I study

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 552-558

  Horsmans, Yves ^a   Hu, Ke ^b   Ruffin, Matthieu ^b   Wang, Ying ^b   Song, Dongweon ^b   Bouillaud, Emmanuel ^d   Wang, Yanfeng ^b   Mazur, Dago ^c   Botha, Frans Peter ^c   Heuman, Douglas M ^d  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PAREXEL INTERNATIONAL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

hepatic impairment; Pasireotide; pharmacokinetics; SOM230; somatostatin analogue

Indexed keywords

PASIREOTIDE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPERGLYCEMIA; INJECTION SITE ERYTHEMA; LIVER DYSFUNCTION; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; VERTIGO;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SOMATOSTATIN; YOUNG ADULT;

EID: 84859071474     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011400072     Document Type: Article

References (15)

1. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286: 69-74. (Pubitemid 351680237)
2. Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95:2781-2789.
3. Kvols L, Glusman JE, Hahn EA, et al. The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. J Clin Oncol. 2007;25(18S):abstract 4558.
4. Kvols L, Oberg K, O'Dorisio TM, et al, on behalf of the Pasireotide Carcinoid Study Group. Efficacy, safety and pharmacokinetic results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR. Neuroendocrinology. 2010;92(1):abstract C57.
5. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): A multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94:115-122.
6. Ben-Shlomo A, Melmed S. Pasireotide-a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs. 2007;10:885-895. (Pubitemid 350179091)
7. Colao A, Petersenn S, Newell-Price J, et al. Pasireotide (SOM230) demonstrates efficacy in patients with Cushing disease: results from a large, randomized-dose, double-blind, phase III study. Endocr Rev. 2011;32(03):abstract OR09-6.
8. Ma P, Wang Y, Van Der Hoek J, et al. Pharmacokineticpharmacodynamic comparison of anovel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther. 2005;78:69-80. (Pubitemid 40956933)
9. Hu K, Zhang Y, Jung J, et al, on behalf of the Pasireotide Acromegaly Study Group. Pasireotide (SOM230) provides biochemical control in patients with active acromegaly: pharmacokinetic/ pharmacodynamic (PK/PD) results from a randomized, multicenter, phase II trial. Presented at: Annual Meeting of the Endocrine Society; June 10-13, 2009; Washington, DC. Abstract P3-677.
10. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
11. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42(suppl):S100-S107. (Pubitemid 40364609)
12. Food and Drug Administration. Guidance for Industry: Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. 2003. Available at: http://www.fda.gov/downloads/Drugs/ Guidance ComplianceRegulatoryInformation/Guidances/ucm072123.pdf.
13. European Medicines Agency (EMEA). Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients With Impaired Hepatic Function. 2005. http://www.ema.europa.eu/pdfs/ human/ewp/233902en.pdf.
14. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181. (Pubitemid 36962641)
15. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117:24-32. (Pubitemid 46048446)